Keyphrases
Systemic Lupus Erythematosus Patient
65%
Systemic Lupus Erythematosus
52%
Lupus
45%
Peruvian
41%
SLE Disease Activity Index (SLEDAI)
38%
Damage Accrual
35%
Age at Diagnosis
31%
Damage Index
30%
Health-related Quality of Life
28%
SLICC
23%
Disease Duration
23%
Latin American
22%
Disease Activity
22%
Multivariable
22%
Patient Data
21%
Remission
21%
Confidence Interval
20%
Granulomatosis with Polyangiitis
14%
Disease Activity Score
14%
Lupus Low Disease Activity State (LLDAS)
13%
Prednisone
12%
American College of Rheumatology
12%
Rheumatology
11%
Homocysteine Levels
10%
Mestizo Population
10%
Serum Uric Acid
10%
ANCA-associated Vasculitis
10%
CD4+CD28null
10%
Low Disease Activity State
10%
Metabolic Syndrome
10%
Visual Analog Scale
10%
Multi-ethnic
10%
Prolactin Levels
10%
Tertiary Care Hospital
10%
Systemic Lupus International Collaborating Clinics
10%
Mestizo
10%
Microscopic Polyangiitis
9%
Immunosuppressive Drugs
9%
Numerical Rating Scale
9%
LupusQoL
8%
Antimalarial Use
8%
Demographic Characteristics
8%
Odds Ratio
8%
Disease Damage
8%
Hazard Ratio
8%
Prolactin
7%
Activity State
7%
Risk Factors
7%
Classification Criteria
7%
Emotional Health
6%
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Disease Activity
46%
Lupus Erythematosus
43%
SLEDAI
28%
Quality of Life
22%
Rheumatology
19%
Disease Duration
17%
ANCA Associated Vasculitis
16%
Patient-Data
16%
Granulomatosis with Polyangiitis
14%
Antimalarial Agent
12%
Prednisone
11%
Uric Acid
10%
Homocysteine
10%
Disease
10%
Microscopic Polyangiitis
9%
Immunosuppressive Drug
9%
Visual Analog Scale
7%
Hazard Ratio
7%
Numeric Rating Scale
7%
Predictive Factor
6%
Socioeconomic Status
6%
Hand-Schüller-Christian Disease
5%
Kidney Injury
5%
Frailty
5%
Tertiary Care
5%
Patient Experience
5%
Medicine
5%
T Cell
5%
CD8 Antigen
5%
Rheumatic Disease
5%
Metabolic Syndrome
5%
Disease Activity Score
5%
Rheumatoid Arthritis
5%
Clinical Feature
5%
Prolactin
5%
Salmonella
5%
Osteomyelitis
5%
Odds Ratio
5%
Proportional Hazards Model
5%
Emotional Stability
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
89%
Disease Activity
52%
Remission
24%
Disease Duration
19%
ANCA Associated Vasculitis
16%
Wegener Granulomatosis
16%
Disease
13%
Uric Acid
10%
Homocysteine
10%
Microscopic Polyangiitis
10%
Immunosuppressive Agent
9%
Antimalarial Agent
7%
Prednisone
7%
Eosinophilic Granuloma
6%
Vasculitis
6%
Kidney Injury
5%
Metabolic Syndrome X
5%
Lupus Erythematosus
5%
Rheumatic Disease
5%
Disease Activity Score
5%
Rheumatoid Arthritis
5%
Clinical Feature
5%
Prolactin
5%
CD8 Antigen
5%